56 results about "Cellular antigens" patented technology

This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.

Methods of treating colon cancer with antibodies that specifically bind to human cytotoxic T-lymphocyte antigen 4 (CTLA-4) are provided.

The application discloses a tandem antigen epitope peptide of G protein of Paralichthys olivaceus rhabdovirus and application thereof, and belongs to the field of fish molecular immunology. The amino acid sequence of the tandem antigen epitope peptide is shown as SEQ ID NO:1. The preparation method of the application comprises the following steps: (1) first, analyzing the structural characteristics of HIRRV-G protein and predicting B cell antigen epitopes, and synthesizing the antigen epitopes with advantages based on the prediction results; (2) then, screening candidate peptide segments with high affinity through enzyme-linked immunosorbent assay; (3) sequentially connecting the high-affinity peptide segment sequences meeting the requirements by using a GPGPG linker, and cloning the connected sequences into a pET-28a prokaryotic expression vector, so that the tandem antigen epitope peptide is obtained after induced expression. Compared with the full-length G protein, the tandem antigen epitope peptide has smaller molecular weight, stronger stability and stronger hydrophilicity; the tandem antigen epitope peptide can induce a large amount of specific antibodies in fish bodies, and significantly reduces the mortality of fish infected by the virus. The tandem antigen epitope peptide can be used for the development of HIRRV diagnostic reagents and subunit vaccines.

Disclosed herein are polypeptides and polypeptide complexes that are capable of binding tumor cell antigens and effector cell antigens. In some embodiments, the polypeptides and polypeptide complexes bind the tumor cell antigens and the effector cell antigens in a tumor microenvironment.

The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an antigen selected from the group consisting of Prostate Stem Cell Antigen (PSCA), B-Lymphocyte antigen CD19 (CD19), hepatocyte growth factor receptor (C-MET), Endosialin, the EGF-like domain 1 of EpCAM, encoded by exon 2, Fibroblast activation protein alpha (FAP alpha) and Insulin-like growth factor I receptor (IGF-IR or IGF-1R). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.

Immunoglobulin complementarity determining regions ("CDRs"), and immunoglobulin binding domains comprising those CDRs, that bind human lymphocyte antigen 6 family member G6D (LY6G6D), for the preparation of multispecific LY6G6D / CD3 binding proteins and their use in a multispecific format with a CD3-binding moiety.

The invention provides a cascade response self-assembly polypeptide for remodeling tumor cell antigen composition, a bioactive solution of the cascade response self-assembly polypeptide and application of the cascade response self-assembly polypeptide. The polypeptide sequentially comprises a hydrophobic end-capping group, an alkaline phosphatase response self-assembly polypeptide sequence, a reduced glutathione response sequence and a T cell epitope peptide sequence. The polypeptide can respond to high-expression alkaline phosphatase in a tumor microenvironment to generate self-assembly and promote efficient internalization of cells; then, the antigen peptide is released under the action of reductive glutathione in tumor cells, and the antigen complex is given to the tumor cells through a main histocompatibility complex I-type molecular antigen presentation pathway. In addition, the specific hydrophobic end-capping group can up-regulate expression of I-type molecules of main histocompatibility complexes of tumor cells, enhance antigen presentation and remarkably enhance the recognition and killing efficiency of antigen-specific T cells on the tumor cells. Combined adoptive immunity and immune checkpoint inhibitor therapy is suitable for combined immunotherapy of solid tumors.

This invention relates to the field of irregular antibody detection technology, specifically to an automated washing microfluidic chip for irregular antibody detection. The chip includes a chip body, a membrane, and a detection component comprising a sample application chamber and a detection chamber arranged sequentially away from the center of rotation. The sample application chamber and the detection chamber are connected by a washing channel. The detection component is pre-filled with a washing solution that can fill the detection chamber and the washing channel under centrifugation. The washing solution contains anti-human immunoglobulin that reacts with erythrocyte antigen-antibody complexes. The specific gravity of the washing solution is configured to be greater than the specific gravity of the sample to be tested but less than the specific gravity of the erythrocyte antigen. This configuration solves the problems of cumbersome procedures, excessive time consumption, high operator dependence, and difficulty in standardization caused by multiple manual washing steps required in traditional test tube methods for detecting irregular antibodies. It effectively ensures detection sensitivity and accuracy and reduces the false negative rate.

This invention belongs to the field of biodetection technology, specifically relating to a material for detecting anti-NF155 antibodies and its preparation method. This invention constructs an expression plasmid capable of highly expressing the NF155 antigen, transfects it into HEK293T cells, and modifies the pCDH vector with enhancers during construction. Subsequently, a modified cell culture protocol is used to obtain a material for detecting anti-NF155 antibodies based on a cell immunofluorescence methodology. This invention uses a cell immunofluorescence methodology to maximize the preservation of the antigen's spatial conformation through cell expression and antigen immobilization, preventing false negatives due to changes in binding sites. This invention selects the lentiviral vector pCDH to avoid the problem of non-specific binding that is difficult to distinguish, as the proteins expressed by common target gene vectors such as pcDNA3.1 may themselves contain antibody binding sites. This improves detection specificity and solves the problem of false negatives.

The invention discloses a recombinant bacillus calmette-guerin vaccine for expressing O and A type multi-epitope fusion peptides of foot and mouth disease viruses and application of the recombinant bacillus calmette-guerin vaccine, and belongs to the field of biotechnology and veterinary vaccines. The amino acid sequence of the multi-epitope fusion peptide is shown as SEQ ID NO: 1, the multi-epitope fusion peptide comprises dominant immune T cell and B cell antigen epitopes from a plurality of O-type and A-type foot-and-mouth disease virus epidemic strains, and a mycobacterium signal peptide is fused at the N terminal. The recombinant strain rBCG-MIPGA is successfully constructed by carrying out codon optimization on the fusion gene, cloning the fusion gene to a pMV306 vector and carrying out electrotransfection on BCG. The recombinant BCG can simultaneously excite high-titer specific antibodies aiming at foot-and-mouth disease virus type O and type A and remarkable T cell immune response, shows lasting and broad-spectrum protection potential, and has great application value in the aspect of preparing safe, efficient and broad-spectrum foot-and-mouth disease vaccines.

The present invention relates to the use of chimeric antigen receptors (CARs) that bind to the B lymphocyte antigen CD19 (cluster of differentiation 19) and T cells expressing such CARs for the treatment of autoimmune diseases, such as systemic lupus erythematosus (SLE).

The present disclosure relates to multispecific molecules comprising a peptide-MHC complex and an immune cell antigen targeting moiety. Particular embodiments relate to multimeric (e.g., dimeric) molecules comprising a peptide-MHC complex, an immune cell antigen targeting moiety, and a multimerization moiety. The present disclosure further provides pharmaceutical compositions comprising the multispecific molecules, and methods of using the multispecific molecules in antigen-specific T cell activation, in inducing antigen-specific immune responses, and in therapeutic applications, as well as nucleic acids encoding the multispecific molecules, recombinant cells expressing the multispecific molecules, and methods of producing the multispecific molecules.

The present invention provides a means or the like capable of temporarily inhibiting expression of PD-1 or CTLA-4 protein. The present invention relates to an antisense oligonucleotide or the like capable of hybridizing with a nucleic acid sequence of an mRNA precursor and / or mature mRNA of Programmed Cell Death 1 (PD-1) protein or Cytotoxic T-lymphocyte Antigen-4 (CTLA-4) protein and suppressing or inhibiting the expression of PD-1 protein or CTLA-4 protein.

The present invention relates to: a composition for delivering a viral antigen-derived CD8+ T cell antigen epitope or a peptide comprising same to the cytoplasm of a target cell to thereby present the epitope or peptide to major histocompatibility complex class I (MAC-1), which is an antigen-presenting molecule on the cell surface; a composition comprising same; and a use thereof.

The invention discloses a camel source single-domain antibody CB3 for recognizing linear B cell epitope in clostridium difficile methylase CamA and application of the camel source single-domain antibody CB3. The nucleotide sequence of the camel source single-domain antibody CB3 is as shown in SEQ ID NO: 1, and the amino acid sequence of the camel source single-domain antibody CB3 is as shown in SEQ ID NO: 2. The camel source single-domain antibody CB3 disclosed by the invention has the advantages of strong specificity, high sensitivity, good accuracy and the like, and it is proved that the camel source single-domain antibody CB3 can be used for detecting recombinant expressed CD-CamA and endogenous CD-CamA by methods such as enzyme-linked immunosorbent assay (ELISA) and western blot hybridization (WB).

The invention relates to a detection kit for a peripheral blood complete immune cell lineage and a door analysis model thereof. The detection kit comprises a monoclonal antibody which is combined with a peripheral mononuclear cell antigen and is marked by 33 rare metal elements. The detection method comprises the following steps: (1) a PBMC (peripheral blood mononuclear cell) acquisition unit: carrying out PBMC separation on a human peripheral blood sample; (2) a living cell bar code marking unit: performing dyeing marking on a plurality of PBMC samples by using a CD45 antibody combination marked by three different metal elements; (3) a sample dyeing unit: mixing a plurality of samples marked by bar codes, and performing dyeing incubation by using prepared 28 metal marked antibodies mix; and (4) a data acquisition unit: performing detection by using a mass spectrometer to obtain original data of the mixed samples. According to the method, rapid and accurate analysis of multi-sample high-dimensional data can be realized, the consumption of precious samples is remarkably reduced, and the cost benefit is considered.

The utility model discloses an automatic sample adding device for cell antibody detection, and particularly relates to the technical field of medical scientific research instruments, the automatic sample adding device comprises a supporting plate, a top plate is fixedly arranged on the front side of the supporting plate, a first electric push rod is fixedly arranged at the bottom of the top plate, and a U-shaped plate is fixedly arranged at the output end of the first electric push rod; a sample adding assembly is arranged at the bottom of the U-shaped plate, a sliding frame is fixedly arranged at the top of the supporting plate, a sliding block is arranged at the top of the sliding frame in a sliding mode, a glass dish is rotationally connected to the top of the sliding block, two concave blocks are arranged on one side of the glass dish, the two concave blocks are fixedly connected with the sliding block, and a moving assembly is arranged on the front side of the sliding frame. According to the utility model, the sample adding assembly is arranged, so that the functions of more accurately controlling the suction amount, the injection speed and the injection force of an antigen sample are realized, and the problem that the test result is easily influenced because the force and the dosage of sample adding each time are generally different when a cell antigen test is manually detected is solved.

The presently disclosed subject matter provides cells, compositions, and methods for inducing B cell depletion. It relates to cells comprising an antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR)) targeting a B cell antigen (e.g., CD19, FcRLS, etc.).

Described herein are heteromultimeric proteins comprising at least two different polypeptide chains. The polypeptides may comprise Cε3 domain and / or Cε4 domain derived from an immunoglobulin E, and a Cγ2 and / or a Cγ3 domain derived from an immunoglobulin G. The two polypeptide chains may preferentially heterodimerize to promote formation of the heteromultimer. The two polypeptide chains may bind to two different target molecules, e.g. a cancer antigen and a T cell antigen.

The present disclosure provides methods for treating a subject having lung cancer, the methods comprising administering to the subject a therapeutically effective amount of: (a) an antibody or antigen-binding portion thereof that specifically binds to the Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) an antibody or antigen-binding portion thereof that specifically binds to Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.

The application provides an antigen epitope polypeptide and a paralichthys ovatus mucin Muc5b specific antibody prepared by the antigen epitope polypeptide, a B cell antigen epitope of the paralichthys ovatus Muc5b protein is screened, the amino acid sequence of the B cell antigen epitope is shown as NDKQRSKQCEDYQVV, a New Zealand white rabbit is immunized after the antigen epitope is coupled with a KLH carrier protein, and a rabbit anti-paralichthys ovatus Muc5b specific antibody is prepared. The antibody can specifically recognize the Muc5b protein in paralichthys ovatus mucosa tissue and positive mucous cells, and provides a key detection tool for in-depth exploration of the function mechanism of mucous cells in the paralichthys ovatus mucosa immune response process.

The presently disclosed subject matter provides cells, compositions, and methods for inducing B cell depletion. It relates to cells comprising an antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR)) targeting a B cell antigen (e.g., CD19, FcRLS, etc.).

Disclosed are methods for treating a cancer and / or modulating immune CD4+ T cell mediated therapies comprising administering to a subject a fucose. In one aspect, disclosed herein are methods of modulating major histocompatibility complex II human lymphocyte antigen (HLA)-DRB 1 expression on the surface of a cell comprising contacting the cell with an agent that modulates the amount of fucosylation on the cell; wherein an increase in fucosylation increases surface expression of HLA-DRB 1; and wherein a decrease in fucosylation decreases the surface expression of HLA-DRB 1.

This invention discloses a chimeric peptide cFel d1-4 based on T-cell antigenic epitopes of feline allergen proteins Fel d1 and Fel d4, its encoding nucleic acid, and its applications, relating to the field of molecular biology. This invention provides a chimeric peptide cFel d1-4, comprising the region represented by amino acid residues 26-41, 46-59, 85-98, 132-140, and 146-153 of the feline allergen Fel d1 antigen, and the region represented by amino acid residues 1-12, 36-48, 83-94, 114-130, and 160-168 of Fel d4. Experiments of this invention demonstrate that the chimeric peptide cFel d1-4 immunizes animals and yields high antibody titers, simultaneously reducing the levels of both feline allergens Fel d1 and Fel d4 proteins.

Provided is a GUCY2C T cell antigen coupler (TAC) polypeptide having (i) an antigen binding domain (e.g., a nanobody) that binds GUCY2C, (ii) an antigen binding domain that binds a protein associated with the TCR complex, and (iii) a T cell receptor signaling domain polypeptide.

Compositions and methods for treating general persistent viral infections, particularly long COVID, are described. The compositions comprise T cells, antigen presenting cells (APCs), and optionally NK cells derived from a patient's whole blood. The APCs are genetically engineered to comprise nucleic acids encoding antigenic peptide sequences for MHC-complexed cell surface expression, where further exposure to an IL-15 agonist and patient T cells can produce activation and expansion of virus-educated T cells for readministration to the patient, thereby targeting cells harboring the virus to T cell-mediated cytotoxicity.

The present application relates to a kind of acute leukemia (ALL) high flux flow detection kit, belong to leukemia detection field, the present application is based on the original 8 color flow to increase 16 kinds of ALL cell antigen, can realize the simultaneous detection of 24 kinds of antigens in the same cell, not only greatly improve the detection precision of micro residual lesion (MRD), and by being divided into 12 development stages to ALL cell, can more accurately identify immunotyping when first diagnosis, and immunophenotypic aberration after bone marrow transplantation and after CAR-T cell therapy, this has very important guiding significance to the evaluation of patient treatment effect and the adjustment of treatment scheme.

The present application belongs to the technical field of immunotherapy, and particularly relates to an antigen epitope peptide of lymphocyte antigen 6 complex site K and application thereof. The present application aims to provide a new method for treating or clinically detecting tumors with high expression of LY6K. The technical scheme of the present application is an antigen epitope peptide of lymphocyte antigen 6 complex site K, and the amino acid sequence is shown in SEQ ID No. 7. The present application provides an LY6K antigen epitope peptide, and the antigen epitope peptide can be used to prepare a pMHC complex or directly load an antigen presenting cell to activate T cells. Therefore, the antigen epitope peptide can be applied to the treatment or diagnosis of tumors with high expression of LY6K antigen.

This invention discloses a graph reasoning and analysis system for addressing defects in cellular antigen processing, belonging to the field of knowledge graph reasoning technology, to solve the problem of slow interpretable localization of defect presentation. This invention constructs a detection likelihood set by integrating HLA typing, somatic cell variation, transcriptomic expression, immunopeptidomics, and surface HLA detection. It assembles direct and cross-presentation subgraphs using pattern gating and loading complex integrity rules, generating reachable paths and observation consistency matrices. It distinguishes between structural contradictions and detection limitations, performs node pruning and link contraction based on constraint propagation to form an individualized graph, and outputs defective nodes and paths based on minimum interpretable paths and causal graph cost search. It generates validation and intervention lists and clinical decision support outputs, thereby reducing unnecessary detection and intervention attempts and improving the timeliness and consistency of case analysis and strategy formulation.

This invention discloses a recombinant BCG vaccine expressing a multi-epitope fusion peptide of foot-and-mouth disease virus (FMD) types O and A and its application, belonging to the fields of biotechnology and veterinary vaccines. The amino acid sequence of the multi-epitope fusion peptide is shown in SEQ ID NO:1, containing dominant immune T-cell and B-cell antigenic epitopes from multiple circulating FMD virus types O and A, and fused with a mycobacterial signal peptide at the N-terminus. This invention successfully constructed the recombinant strain rBCG-MIPGA by codon optimization of the fusion gene, cloning it into the pMV306 vector, and electroporating it into BCG. This recombinant BCG can simultaneously stimulate high-titer specific antibodies and significant T-cell immune responses against FMD virus types O and A, exhibiting durable and broad-spectrum protective potential, and has significant application value in the preparation of safe, efficient, and broad-spectrum FMD vaccines.